Showing 5241-5250 of 21466 results for "".
- Sun Pharma Previews Long-Term UNLOXCYT Follow-Up at ASCO 2026https://reachmd.com/news/sun-pharma-previews-long-term-unloxcyt-follow-up-at-asco-2026/2487216/Key Takeaways: Sun Pharma will present long-term follow-up data from the pivotal trial of UNLOXCYT (cosibelimab-ipdl) at the 2026 ASCO Annual Meeting. The data focus on patients with metastatic or locally advanced cutaneous squamous cell carcinoma (cSC
- ERAS In Older Adults Undergoing Major Abdominal Surgeryhttps://reachmd.com/news/eras-in-older-adults-undergoing-major-abdominal-surgery/2487219/Key Takeaways ERAS was associated with shorter length of stay and fewer total complications than conventional perioperative care. Thirty-day readmission was not significantly different, and the mortality estimate favored ERAS but warranted cautious int
- S-SMARTS Technique Demonstrates Early Promise in Breast Reconstruction Studyhttps://reachmd.com/news/s-smarts-technique-demonstrates-early-promise-in-breast-reconstruction-study/2487205/Investigators from Osaka University reported favorable early oncologic and cosmetic outcomes with a novel breast-conserving surgery reconstruction approach known as S-SMARTS, according to a feasibility study published online ahead of print in
- Ultrasound Detects Subclinical Joint and Nail Changes in Pediatric Psoriasishttps://reachmd.com/news/ultrasound-detects-subclinical-joint-and-nail-changes-in-pediatric-psoriasis/2487206/Musculoskeletal ultrasound may help identify early inflammatory changes in children with psoriasis before the onset of clinically apparent arthritis, according to findings from a pilot study evaluating joint, entheseal, and nail abnormalities in pediatric patients.
- Abatacept Versus Hydroxychloroquine in Palindromic Rheumatism Trialhttps://reachmd.com/news/abatacept-versus-hydroxychloroquine-in-palindromic-rheumatism-trial/2487184/Key Takeaways Over 24 months, abatacept was associated with less progression to rheumatoid arthritis than hydroxychloroquine in this seropositive palindromic rheumatism cohort. Remission was more common and attack intensity was lower with abatacept, wh
- MARS-ED Trial: Machine Learning Risk Stratification In The EDhttps://reachmd.com/news/mars-ed-trial-machine-learning-risk-stratification-in-the-ed/2487185/Key Takeaways Prognostic discrimination with RISKINDEX was at least as high as the clinician intuition questions and higher than the standard scores examined in this trial. Treatment plans changed in 1 of 644 intervention patients, and admission, lengt
- Pasteurized Akkermansia Muciniphila MucT In Weight Loss Maintenancehttps://reachmd.com/news/pasteurized-akkermansia-muciniphila-muct-in-weight-loss-maintenance/2487191/Key Takeaways MucT was associated with less weight regain than placebo during the maintenance phase. Net weight loss from baseline to the end of maintenance was greater with MucT than with placebo. Initial Akkermansia spp. abundance was associ
- Tirzepatide Maintained Weight Loss In SURMOUNT-MAINTAINhttps://reachmd.com/news/tirzepatide-maintained-weight-loss-in-surmount-maintain/2487192/Key Takeaways Continued tirzepatide at the maximum tolerated dose was associated with greater maintenance of bodyweight reduction than switching to placebo at week 112. The 5 mg group showed an intermediate result, and rescue therapy after substantial
- Molecular Profiling Guides Adjuvant Therapy in Endometrial Cancerhttps://reachmd.com/news/molecular-profiling-guides-adjuvant-therapy-in-endometrial-cancer/2487196/Key Takeaways Non-inferiority for vaginal recurrence was reported, although recurrence was numerically higher with molecular-profile guided treatment. Favorable profiles were assigned to observation, intermediate profiles to brachytherapy, and unfavora
- FDA Clears Caliway’s Phase 3 CBL-514 Trial for Abdominal Fat Reductionhttps://reachmd.com/news/fda-clears-caliways-phase-3-cbl-514-trial-for-abdominal-fat-reduction/2487183/Caliway Biopharmaceuticals announced that the US Food and Drug Administration (FDA) cleared the Investigational New Drug application for CBL-0302, also known as SUPREME-02, its second global pivotal phase 3 study of CBL-514 for abdominal subcutaneous fat reduction.1 The IND pass